FDA Clearance Tracker · P080011-S141
Ethos AquaTech Monthly XR, Ethos AquaTech Monthly XR for Astigmatism
Last checked: Nov 20, 2026Latest source record: Sep 19, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Sep 19, 2022
Approved
Time to decision
180 days
Received Mar 23, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P080011-S141
- Device name
- Ethos AquaTech Monthly XR, Ethos AquaTech Monthly XR for Astigmatism
- Applicant
- CooperVision, Inc.
- Applicant location
- San Ramon, CA
- Received
- Mar 23, 2022
- Decided
- Sep 19, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P080011
Device type
- Device type
- Lenses, soft contact, extended wear (LPM)
- Device class
- Class III
- Regulation
- 21 CFR 886.5925
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for the following new private label brand names: Ethos AquaTech Monthly XR and Ethos AquaTech Monthly XR for astigmatism
Source documents
Other decisions for CooperVision, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K234127 · Decided Jan 25, 2024 · 28 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.